Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico - Concepedia

Concepedia

Publication | Closed Access

Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico

62

Citations

18

References

2010

Year

Juan Sierra‐Madero, Angelina Villası́s-Keever, Patricia Méndez, Juan Luis Mosqueda-Gómez, Indiana Torres-Escobar, Fernanda Gutiérrez-Escolano, Irene Juárez-Kasusky, Martín Magana-Aquino, Carmen Ramos-Santos, Leticia Pérez-Saleme,

JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

In these very advanced HIV-infected ARV-naive subjects, EFV-based highly active antiretroviral therapy had superior virologic efficacy than LPV/r-based highly active antiretroviral therapy, with a more favorable lipid profile.

References

	Year	Citations

Page 1